Menu
Montecito
Pac Premier
Giving Guide
Loading...
You are here:  Home  >  'Xgeva'
Latest

Amgen closes deal for $2.8B stake in oncology firm BeiGene

By   /  Friday, January 10th, 2020  /  Latest news  /  Comments Off on Amgen closes deal for $2.8B stake in oncology firm BeiGene

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

New drugs boost profits at Amgen as two executives leave company

By   /  Friday, August 3rd, 2018  /  Central Coast Health Watch, Earnings, East Ventura County, left, Tri-County Public Companies  /  Comments Off on New drugs boost profits at Amgen as two executives leave company

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Amgen earnings per share up 20 percent due to higher product sales

By   /  Thursday, July 26th, 2018  /  Central Coast Health Watch, Earnings, East Ventura County, Latest news, Tri-County Public Companies  /  Comments Off on Amgen earnings per share up 20 percent due to higher product sales

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

European Union approves Amgen’s Xgeva to treat multiple myeloma

By   /  Tuesday, April 3rd, 2018  /  Central Coast Health Watch, Latest news, Technology, Tri-County Public Companies  /  Comments Off on European Union approves Amgen’s Xgeva to treat multiple myeloma

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Amgen wins new FDA approval for cancer drug Xgeva

By   /  Friday, January 5th, 2018  /  Central Coast Health Watch, East Ventura County, Latest news, Tri-County Public Companies  /  Comments Off on Amgen wins new FDA approval for cancer drug Xgeva

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Amgen asks FDA to consider new uses for Xgeva

By   /  Monday, June 19th, 2017  /  Central Coast Health Watch, East Ventura County, Latest news, Tri-County Public Companies  /  Comments Off on Amgen asks FDA to consider new uses for Xgeva

Thousand Oaks-based biotech giant Amgen announced June 19 that the U.S. Food and Drug Administration has accepted a supplemental application for Xgeva (denosumab) that seeks to expand the currently approved indication for the prevention of fractures and other skeletal-related events in patients with bone metastases from solid tumors to include patients with multiple myeloma. “Multiple Read More →

Read More →
Latest

Amgen reports revenue increase in second quarter earnings

By   /  Wednesday, July 27th, 2016  /  Central Coast Health Watch, Earnings, Latest news, Tri-County Public Companies, West Ventura County  /  Comments Off on Amgen reports revenue increase in second quarter earnings

Updated on July 27 at 4 p.m.: Amgen reported a 6 percent increase in revenue and a 15 percent increase in earnings per share in its second quarter earnings released July 27. Revenues grew to $5.7 billion due to higher sales of the company’s drugs Enbrel, Prolia, Kyprolis and Xgeva, and operating income increased 15 Read More →

Read More →